A blood lipid lowering Chinese medicinal composition containing Panax notoginseng and Pueraria root and preparation method thereof

By extracting active ingredients from Panax notoginseng and Pueraria root, an efficient and safe Chinese medicine composition was prepared, which solved the problems of different efficacy and side effects of existing blood lipid-lowering drugs, and achieved significant blood lipid-lowering effects, which were particularly suitable for sensitive people .

CN117919301BActive Publication Date: 2024-12-03云南药食同源健康管理有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410121064.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-29
Publication Date
2024-12-03
Estimated Expiration
2044-01-29

AI Technical Summary

Technical Problem

The existing blood lipid-lowering drugs have different efficacy and have side effects, especially for sensitive people such as pregnant women, children, and the elderly, and it is difficult to meet the efficient and safe blood lipid-lowering needs.

Method used

A Chinese medicine composition containing Panax notoginseng and Pueraria root is developed, and the active ingredients are extracted from plants through processes such as pulverization, leaching, extraction of ethanol aqueous solution, resin adsorption and elution, and a Chinese medicine composition that is efficiently lowered in blood lipids is prepared.

Benefits of technology

This composition has high efficiency in reducing the levels of TC, TG and HDL-C in the blood, is highly safe, has no toxic side effects, and has significant effect on reducing blood lipids in 30 days, especially when the extraction ratio of Panax notoginseng and Pueraria root is 1.5-3:1, the effect is the most effective Excellent, the extraction process enhances the efficacy of lowering blood lipids.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to the field of pharmaceutical technology, and in particular to a Chinese medicine composition for lowering blood lipids containing Panax notoginseng and Pueraria root and a preparation method thereof. The process for preparing the composition of the present invention comprises crushing and mixing raw materials Panax notoginseng and Pueraria root, extracting with ethanol aqueous solution, concentrating the extract, then extracting with a composite solvent, concentrating the extract, adsorbing and eluting with a resin, and concentrating and drying. The composition provided by the present invention has a high-efficiency blood lipid-lowering effect, and the active ingredients are extracted from plants, and has the functions of high safety and no toxic side effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medicines, and in particular to a blood lipid lowering Chinese medicinal composition containing notoginseng and kudzu root and a preparation method thereof. Background Art

[0002] Hyperlipidemia refers to abnormal metabolism or operation of human fat, which causes the blood lipid content in the blood to exceed the normal range, manifested as high cholesterol and triglycerides in the blood and low high-density lipoprotein. With the improvement of people's living standards and lack of attention to diet, hyperlipidemia has become a common disease, and it is gradually becoming younger. Hyperlipidemia will accelerate systemic atherosclerosis. If you do not pay attention to lowering blood lipids and allow hyperlipidemia to continue to develop, it will further lead to the occurrence of cardiovascular and cerebrovascular diseases, such as coronary heart disease, angina pectoris, myocardial infarction, cerebral stroke, etc.

[0003] Hyperlipidemia can be prevented in daily life. The current methods to prevent or reduce hyperlipidemia are: changing eating habits and structure and controlling weight. Generally speaking, obese people are more likely to have hyperlipidemia. Exercise can enhance cardiopulmonary function, promote metabolism, reduce triglyceride and cholesterol levels in the blood, and prevent hyperlipidemia. Medication or health care product treatment, taking health food, Chinese medicine or Western medicine, reducing cholesterol and triglycerides in the blood, regularly adjusting blood lipid indicators, quitting smoking and drinking.

[0004] Among them, changing eating habits, dietary structure, exercising, controlling weight, and quitting smoking and drinking are relatively difficult for people living in modern fast-paced lives, and they usually do not have the conditions and time to maintain their health.

[0005] Taking medicine regularly has become the first choice for modern people to prevent and treat hyperlipidemia. It is more convenient, effective and easy to achieve than changing diet, exercising, quitting smoking and drinking. At present, the ingredients of lipid-lowering drugs and health products are diverse and the efficacy varies. Some drugs are slow to take effect and have a long course of treatment. Some drugs can cause side effects when taken for a long time, especially the effects on liver and kidney function. In addition, for people with different physical constitutions, especially sensitive groups such as pregnant women, children, and the elderly, they should also pay attention to choosing suitable drug ingredients to avoid serious side effects.

[0006] Therefore, developing highly effective and safe lipid-lowering drugs is an urgent problem to be solved. Summary of the invention

[0007] The present invention is based on solving the above technical problems, and thus proposes the technical solution of the present invention. The technical solution of the present invention includes a blood lipid lowering Chinese medicine composition containing Panax notoginseng and Pueraria lobata and a preparation method thereof.

[0008] The composition provided by the present invention has a highly effective blood lipid-lowering effect, and the active ingredients are extracted from plants, and has the functions of high safety and no toxic side effects. The process for preparing the composition of the present invention comprises crushing and mixing raw materials Panax notoginseng and Pueraria root, extracting with ethanol aqueous solution, concentrating the extract, then extracting with a composite solvent, concentrating the extract, resin adsorption and elution, and concentrating and drying processes.

[0009] The present invention extracts active ingredients from Radix Notoginseng and Radix Puerariae to obtain a blood lipid lowering composition.

[0010] In one aspect, the present invention provides a method for preparing a lipid-lowering Chinese medicine composition containing Panax notoginseng and Pueraria root, characterized in that it comprises the following steps:

[0011] Step 1: Grind dried Panax notoginseng and Pueraria root separately, and mix the ground powders to obtain a powder mixture;

[0012] Step 2: adding ethanol aqueous solution, heating, stirring, filtering, obtaining a filtrate, and concentrating the filtrate to obtain a concentrate 1;

[0013] Step 3: adding an extraction solvent consisting of an organic solvent phase and an aqueous phase to the concentrate 1, heating and extracting, and concentrating the extracted aqueous phase to obtain a concentrate 2;

[0014] Step 4: adsorb the concentrate 2 using a macroporous resin, elute using water, and then elute using an ethanol aqueous solution, collect the eluate 1 eluted with water and the ethanol aqueous solution, concentrate, and dry to obtain the composition.

[0015] Furthermore, the particle sizes of the Panax notoginseng and Pueraria root after crushing are 0.1mm-100mm, and can also be 0.2-80mm, 0.3-60mm, 0.4-50mm, 0.5-40mm, and 0.5-10mm.

[0016] Furthermore, the mass ratio of the Panax notoginseng powder to the Pueraria powder is 1.5-3:1, and can also be 1.6:1, 1.8:1, 2:1, 2.2:1, 2.5:1, 2.8:1, or a range consisting of any two of the above ratios.

[0017] Furthermore, the mass concentration of the ethanol aqueous solution in step 2 is 40-75%, and can also be 45-75%, 45-70%, 50-70%, 55-65%, or 55-60%.

[0018] Furthermore, the mass of the ethanol aqueous solution in step 2 is 20-500 times the mass of the powder mixture, and can also be 30 times, 50 times, 80 times, 100 times, 150 times, 200 times, 300 times, 400 times, or a range between any two of the above multiples.

[0019] Furthermore, the heating temperature in step 2 is 40-65°C, and can also be 42-65°C, 45-63°C, 48-62°C, 50-60°C, or 52-58°C.

[0020] Furthermore, the stirring time of step 2 is 0.5-72 hours, or 1-65 hours, 2-55 hours, or 3-48 hours.

[0021] Furthermore, the concentration in step 2 is to remove ethanol to obtain a concentrate 1 whose mass is 0.04-0.3 times, or 0.05-0.2 times, 0.06-0.15 times, or 0.08-0.12 times the mass of the filtrate.

[0022] Furthermore, the organic solvent in step 3 is ethyl acetate and chloroform in a mass ratio of 3-5:1, or 3.2-4.8:1, 3.5-4.5:1, or 3.8-4.2:1.

[0023] Furthermore, the aqueous phase in step 3 is water.

[0024] Furthermore, the mass ratio of the organic solvent phase to the aqueous phase in the extraction solvent of step 3 is 1:2-4, or 1:2.2-3.5, 1:2.5-3.2, or 1:2.8-3.1.

[0025] Furthermore, the mass ratio of the extraction solvent in step 3 to the concentrate 1 is 4-50:1, or 5-45:1, 6-40:1, 8-35:1, or 10-30:1.

[0026] Furthermore, the heating temperature of step 3 is 35-50°C, or 36-50°C, 38-48°C, or 40-45°C.

[0027] Furthermore, the extraction time of step 3 is 0.5-30 hours, or 1-25 hours, 2-20 hours, or 3-15 hours.

[0028] Furthermore, the concentration in step 3 is performed until the mass of the concentrate 2 is 0.05-0.5 times, or 0.07-0.5 times, 0.1-0.4 times, or 0.1-0.3 times the mass of the aqueous phase after extraction.

[0029] Furthermore, the amount of water used in the water elution in step 4 is 3-8 times, or 4-7 times, 4-6 times, or 4-5 times the mass of the concentrate 2.

[0030] Furthermore, the amount of the ethanol aqueous solution used for elution in step 4 is 3-8 times, or 4-7 times, 4-6 times, or 4-5 times the mass of the concentrate 2.

[0031] Furthermore, the mass concentration of the ethanol aqueous solution in step 4 is 40-75%, and can also be 45-75%, 45-70%, 50-70%, 55-65%, or 55-60%.

[0032] Furthermore, the mass of the concentrate in step 4 is 0.01-0.3 times, 0.02-0.2 times, 0.03-0.1 times, or 0.04-0.1 times the mass of the eluent 1.

[0033] Furthermore, the drying in step 4 is freeze-drying.

[0034] On the other hand, the present invention also provides a blood lipid lowering Chinese medicinal composition containing Panax notoginseng and Pueraria root obtained by the preparation method.

[0035] On the other hand, the present invention also provides the use of the traditional Chinese medicine composition in preparing a lipid-lowering drug.

[0036] On the other hand, the present invention also provides a medicine comprising the Chinese medicine composition and a carrier.

[0037] Beneficial effects:

[0038] The present invention extracts active ingredients from Panax notoginseng and Pueraria root to obtain a lipid-lowering composition; the composition provided by the present invention has a high-efficiency lipid-lowering effect, and the active ingredients are extracted from plants, and has the functions of high safety and no toxic side effects.

[0039] The traditional Chinese medicine composition obtained by the process of the present invention has excellent effects of lowering blood TC, TG and HDL-C levels and has excellent blood lipid lowering effect.

[0040] The composition obtained by the preparation process of the present invention can reduce the TC ratio of rats by 58.55%, reduce the TG ratio by 39.19%, and reduce the HDL-C value by 47.4 mg / dL after being used for 30 days.

[0041] In the preparation process of the present invention, Panax notoginseng and Pueraria root are used for extraction to obtain a lipid-lowering composition. After the combination of the two drugs and the extraction process of the present invention, the lipid-lowering effect of the obtained composition has an effect of 1+1 greater than 2. When the extraction amount ratio of Panax notoginseng and Pueraria root reaches the range of 1.5-3:1, the lipid-lowering effect of the obtained composition is better.

[0042] When preparing the composition, the present invention uses an extraction process after using an ethanol aqueous solution for extraction to further enhance the lipid-lowering effect of the composition. In particular, when ethyl acetate and chloroform in the extraction organic solvent phase are combined in a mass ratio of 3-5:1, the lipid-lowering effect of the obtained composition is more significant.

[0043] The preparation method of the product of the invention is simple, green and environmentally friendly, and has broad application prospects. DETAILED DESCRIPTION

[0044] The present invention will be described below in conjunction with specific embodiments, and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific embodiments are used to illustrate the present invention, rather than to limit the present invention.

[0045] 1. Preparation of products

[0046] Product 1: The preparation steps are as follows:

[0047] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 7:3 to obtain a powder mixture;

[0048] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0049] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 4:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0050] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, collecting the eluate 1 eluted with water and the ethanol aqueous solution, and concentrating under reduced pressure to remove ethanol until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-drying to a water content of 4.2wt% to obtain product 1.

[0051] Product 2: The preparation steps are as follows:

[0052] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm to 15 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 1.5:1 to obtain a powder mixture;

[0053] Step 2: adding a 50% ethanol aqueous solution with a mass concentration of 80 times the mass of the powder mixture, heating to 45° C., stirring at a stirring speed of 50 rpm for 4 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.15 times the mass of the filtrate to obtain a concentrate 1;

[0054] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 3:1) and water (deionized water) in a mass ratio of 1:2.8, which is 13 times the mass of the concentrate 1, heating to 40° C. for extraction for 5 hours, and concentrating the extracted water phase under reduced pressure to 0.12 times the mass of the extracted water phase to obtain a concentrate 2;

[0055] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration of 4 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 60% with a mass concentration of 6 times that of the concentrate 2, and the eluate 1 eluted with water and ethanol aqueous solution is collected, and the ethanol is removed by vacuum concentration until the mass of the concentrate is 0.085 times the mass of the eluate 1, and freeze-dried to a water content of 4.1wt% to obtain product 2.

[0056] Product 3: The preparation steps are as follows:

[0057] Step 1: Grind the dried kudzu root to obtain a powder with a particle size of 0.5 mm to 10 mm to obtain a powder;

[0058] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate until the concentrate is 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0059] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 4:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0060] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, collecting the eluate 1 eluted with water and the ethanol aqueous solution, and concentrating under reduced pressure to remove ethanol until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-drying to a water content of 4.2wt% to obtain product 3.

[0061] Product 4: The preparation steps are as follows:

[0062] Step 1: Grind the dried Panax notoginseng to obtain a powder with a particle size of 0.5 mm to 10 mm to obtain a powder;

[0063] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate until the concentrate is 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0064] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 4:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0065] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, collecting the eluate 1 eluted with water and the ethanol aqueous solution, and concentrating under reduced pressure to remove ethanol until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-drying to a water content of 4.2wt% to obtain product 4.

[0066] Product 5: The preparation steps are as follows:

[0067] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 8:2 to obtain a powder mixture;

[0068] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0069] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 4:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0070] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, collecting the eluate 1 eluted with water and the ethanol aqueous solution, and concentrating under reduced pressure to remove ethanol until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-drying to a water content of 4.2wt% to obtain product 5.

[0071] Product 6: The preparation steps are as follows:

[0072] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 5:5 to obtain a powder mixture;

[0073] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0074] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 4:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0075] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, and the eluate 1 eluted with water and ethanol aqueous solution is collected, and the ethanol is removed by concentrating under reduced pressure until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-dried to a water content of 4.2wt% to obtain product 6.

[0076] Product 7: The preparation steps are as follows:

[0077] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 7:3 to obtain a powder mixture;

[0078] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0079] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 1:1) and water (deionized water) phase with a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0080] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, collecting the eluate 1 eluted with water and the ethanol aqueous solution, and concentrating under reduced pressure to remove ethanol until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-drying to a water content of 4.2wt% to obtain product 7.

[0081] Product 8: The preparation steps are as follows:

[0082] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 7:3 to obtain a powder mixture;

[0083] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0084] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 2:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted water phase under reduced pressure to 0.1 times the mass of the extracted water phase to obtain a concentrate 2;

[0085] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, and the eluate 1 eluted with water and ethanol aqueous solution is collected, and the ethanol is removed by concentrating under reduced pressure until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-dried to a water content of 4.2wt% to obtain product 8.

[0086] Product 9: The preparation steps are as follows:

[0087] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 7:3 to obtain a powder mixture;

[0088] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0089] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 6:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted aqueous phase under reduced pressure to 0.1 times the mass of the extracted aqueous phase to obtain a concentrate 2;

[0090] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, and the eluate 1 eluted with water and ethanol aqueous solution is collected, and the ethanol is removed by concentrating under reduced pressure until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-dried to a water content of 4.2wt% to obtain product 9.

[0091] Product 10: The preparation steps are as follows:

[0092] Step 1: Grind dried Panax notoginseng and Pueraria root separately to obtain powder with a particle size of 0.5 mm-10 mm, and then mix the crushed Panax notoginseng powder and Pueraria root powder in a mass ratio of 7:3 to obtain a powder mixture;

[0093] Step 2: adding a 55% ethanol aqueous solution with a mass concentration of 70 times the mass of the powder mixture, heating to 55° C., stirring at a stirring speed of 60 rpm for 5 hours, filtering with a filter membrane with a pore size of 20 μm to obtain a filtrate, and concentrating the filtrate under reduced pressure to remove ethanol and concentrate to a concentrate of 0.1 times the mass of the filtrate to obtain a concentrate 1;

[0094] Step 3: adding an extraction solvent consisting of an organic solvent phase (composed of ethyl acetate and chloroform in a mass ratio of 7:1) and water (deionized water) in a mass ratio of 1:3, which is 15 times the mass of the concentrate 1, heating to 42° C. for extraction for 3.5 hours, and concentrating the extracted aqueous phase under reduced pressure to 0.1 times the mass of the extracted aqueous phase to obtain a concentrate 2;

[0095] Step 4: The concentrate 2 is adsorbed using a macroporous adsorption resin AB-8, eluted using deionized water with a mass concentration that is 5 times that of the concentrate 2, and then eluted using an ethanol aqueous solution with a mass concentration of 55% with a mass concentration that is 5 times that of the concentrate 2, collecting the eluate 1 eluted with water and the ethanol aqueous solution, and concentrating under reduced pressure to remove ethanol until the mass of the concentrate is 0.08 times the mass of the eluate 1, and freeze-drying to a water content of 4.2wt% to obtain a product 10.

[0096] 2. Effect Test

[0097] The effects of the products 1-10 on blood lipids of rats were tested. The effects of the products 1-10 on blood lipids were evaluated by using the changes in the levels of TC, TG and HDL-C in the blood of rats.

[0098] Test samples: Products 1-10 above.

[0099] Experimental animals: Several SD rats, weighing 150-190 g, half male and half female.

[0100] Feed: basic feed (low-fat feed, purchased from Nantong Trophy Feed Technology Co., Ltd.); high-fat feed: 93.8wt% basic feed, 5wt% lard, 1wt% cholesterol and 0.2wt% bile salt.

[0101] Experimental method: After the rats were fed with basic feed for one week, blood was taken from the rats to measure the levels of TC, TG and HDL-C in the blood, and rats with normal indicators were selected for the experiment. Rats with normal indicators were randomly divided into 11 groups, with 10 rats in each group (half male and half female); rats in each group were fed with the same amount of high-fat feed every day; in addition, rats in the high-fat group were gavaged with normal saline once a day (gavage volume 15mL / 100g rat), and product 1-10 groups were gavaged with corresponding products 1-10 once a day (products 1-10 were pre-diluted with normal saline into solution, the gavage volume was 1.5mL solution / 100g rat, and the drug component was 82mg of the above products / 1kg rat). After the feeding and gavage were completed on the 30th day of the experiment, the feeding and gavage treatment were terminated. Blood was taken from the femoral artery of the rats to test the TC, TG and HDL-C values, the reduction rates a and b of TC and TG of the 30-day product group compared with the high-fat group, and the 30-day HDL-C value change value K. Among them, the calculation formulas for a and b are as follows:

[0102] The reduction rate of TC in the product group after 30 days compared with the high-fat group is a=100%×[1-(TC value of the product group at 30 days-TC value of the product group before the test) / (TC value of the high-fat group at 30 days-TC value of the high-fat group before the test)];

[0103] The reduction rate of TG in the product group after 30 days compared with the high-fat group b = 100% × (TG value of the high-fat group at 30 days - TG value of the product group at 30 days) / TG ​​value of the high-fat group at 30 days;

[0104] The change value of HDL-C value in 30 days K = HDL-C value in 30 days - HDL-C value before the test.

[0105] The results are shown in Tables 1-3.

[0106] Table 1: Test of changes in rat blood TC levels

[0107] Group TC value before the test / mg / dL 30-day TC value / mg / dL Reduction rate High fat group 67.02±8.75 88.01±12.98 - Product 1 group 66.56±7.53 75.26±13.47 58.55% Product 2 Group 66.83±8.03 75.85±11.09 57.03% Product 3 Groups 67.14±7.96 78.14±14.62 47.59% Product 4 Groups 66.24±9.15 76.43±10.53 51.45% Product 5 Groups 67.35±7.49 76.94±12.39 54.31% Product 6 Groups 66.47±7.80 76.89±14.90 50.36% Product 7 Groups 66.05±9.43 76.56±10.94 49.93% Product 8 Groups 66.39±8.37 75.97±11.82 54.36% Product 9 Groups 67.48±7.72 77.22±14.37 53.60% Product 10 groups 66.92±7.04 77.19±13.05 51.07%

[0108] Table 2: Test of changes in blood TG levels in rats

[0109] Group TG value before the test / mg / dL 30-day TG value / mg / dL Reduction rate High fat group 43.28±5.84 90.13±16.72 - Product 1 group 44.37±5.27 72.86±15.83 39.19% Product 2 Group 42.95±6.09 71.97±14.96 38.06% Product 3 Groups 43.82±4.58 76.35±15.12 30.57% Product 4 Groups 44.01±5.01 74.92±16.07 34.02% Product 5 Groups 42.16±5.93 72.13±16.94 36.03% Product 6 Groups 42.53±6.35 73.85±15.51 33.15% Product 7 Groups 44.86±4.86 76.33±14.57 32.83% Product 8 Groups 43.57±6.43 73.51±14.03 36.09% Product 9 Groups 41.74±4.77 71.95±15.68 35.52% Product 10 groups 42.65±6.19 73.72±16.45 33.68%

[0110] Table 3: Test of changes in blood HDL-C levels in rats

[0111] Group HDL-C value before the test / mg / dL 30-day HDL-C value / mg / dL Change value K value / mg / dL High fat group 35.76±4.03 37.48±4.28 1.72 Product 1 group 34.82±3.57 30.08±2.62 -4.74 Product 2 Group 35.93±3.09 31.35±3.85 -4.58 Product 3 Groups 34.12±4.26 30.60±2.99 -3.52 Product 4 Groups 35.27±3.73 31.26±3.72 -4.01 Product 5 Groups 34.53±2.98 30.24±4.03 -4.29 Product 6 Groups 36.24±3.15 32.35±3.53 -3.89 Product 7 Groups 35.59±4.54 31.78±3.07 -3.81 Product 8 Groups 36.05±3.92 31.73±4.15 -4.32 Product 9 Groups 34.72±4.41 30.48±3.57 -4.24 Product 10 groups 34.38±2.77 30.41±4.51 -3.97

[0112] From the test results in Tables 1-3, it can be seen that the Chinese medicine composition obtained by the process of the present invention has excellent effects on lowering blood TC, TG and HDL-C levels, and has excellent blood lipid lowering effects.

[0113] The composition obtained by the preparation process of the present invention can reduce the TC ratio of rats by 58.55%, reduce the TG ratio by 39.19%, and reduce the HDL-C value by 47.4 mg / dL after being used for 30 days.

[0114] In the preparation process of the present invention, Panax notoginseng and Pueraria root are used for extraction to obtain a lipid-lowering composition. After the combination of the two drugs and the extraction process of the present invention, the lipid-lowering effect of the obtained composition has an effect of 1+1 greater than 2, which can be obtained from the comparison results of products 1, 3-4. It is speculated that the reason is that after the active ingredients of the two are extracted by the extraction process of the present invention, the lipid-lowering effects exerted produce a mutually reinforcing relationship. When the extraction dosage ratio of Panax notoginseng and Pueraria root reaches the range of 1.5-3:1, the obtained composition has a better lipid-lowering effect.

[0115] When preparing the composition of the present invention, after using ethanol aqueous solution for extraction, an extraction process is used to further enhance the lipid-lowering effect of the composition. In particular, when ethyl acetate and chloroform in the extraction organic solvent phase are combined at a mass ratio of 3-5:1, the lipid-lowering effect of the obtained composition is more significant. This may be because the combination of the extraction organic solvent phase can have better selectivity for impurities, non-lipid-lowering active ingredients or antagonistic lipid-lowering active ingredients in the extract, thereby giving the composition a higher efficacy.

[0116] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A method for preparing a blood lipid lowering Chinese medicinal composition containing Panax notoginseng and Pueraria root, It is characterized in that The steps include: Step 1: Grind dried Panax notoginseng and Pueraria root separately, and then mix the ground powders to obtain a powder mixture; Step 2: adding ethanol aqueous solution, heating, stirring, filtering, obtaining a filtrate, and concentrating the filtrate to obtain a concentrate 1; Step 3: adding an extraction solvent consisting of an organic solvent phase and an aqueous phase to the concentrate 1, heating and extracting, and concentrating the extracted aqueous phase to obtain a concentrate 2; Step 4: adsorbing the concentrate 2 using a macroporous resin, eluting with water, and then eluting with an ethanol aqueous solution, collecting the eluate 1 eluted with water and the ethanol aqueous solution, concentrating, and drying to obtain the composition; The mass ratio of Panax notoginseng powder to Pueraria root powder is 7:3; The mass concentration of the ethanol aqueous solution in step 2 is 40-75%; The mass of the ethanol aqueous solution in step 2 is 20-500 times the mass of the powder mixture; The stirring time of step 2 is 0.5-72 hours; the heating temperature of step 2 is 40-65°C; The organic solvent phase of step 3 is ethyl acetate and chloroform in a mass ratio of 3-5:1; the aqueous phase of step 3 is water; The mass ratio of the extraction solvent in step 3 to the concentrate 1 is 4-50:1; The heating temperature in step 3 is 35-50°C; The amount of the ethanol aqueous solution used for elution with the ethanol aqueous solution in step 4 is 3-8 times the mass of the concentrate 2; The mass concentration of the ethanol aqueous solution in the ethanol aqueous solution elution in step 4 is 40-75%.

2. The preparation method according to claim 1, It is characterized in that The particle sizes of the Panax notoginseng and Pueraria root after crushing are both 0.1mm-100mm.

3. A lipid-lowering Chinese medicine composition containing Panax notoginseng and Pueraria root obtained by the preparation method as described in any one of claims 1-2.

4. Use of the Chinese medicine composition according to claim 3 in preparing a lipid-lowering drug.

5. A drug, It is characterized in that Comprising the Chinese medicine composition according to claim 3 and a carrier.